米格列奈钙片治疗2型糖尿病的临床疗效及安全性观察

发布时间：2018-05-31 11:38

本文选题：米格列奈钙片 + 2型糖尿病　；参考：《吉林大学》2017年硕士论文

【摘要】：目的:以那格列奈片(唐力)为对照评价米格列奈钙片治疗2型糖尿病的临床疗效与安全性。方法:此研究选取2型糖尿病患者56例,随机将56例患者分成试验组和对照组,试验组28例(n=28),对照组28例(n=28)。试验组给予米格列奈钙片治疗16周,口服米格列奈钙片2片/次,3次/天;对照组给予那格列奈片治疗16周,口服那格列奈片1片/次,3次/天。测定两组患者治疗前后糖化血红蛋白(HbA1c),空腹血糖(FPG)、餐后1小时血糖(PPG1)、餐后两小时血糖(PPG2),空腹胰岛素、餐后1小时胰岛素、餐后2小时胰岛素,空腹C肽、餐后1小时C肽、餐后2小时C肽的疗效指标并进行比较。比较两组患者使用米格列奈钙片治疗2型糖尿病的临床疗效及用药安全性。结果:米格列奈钙片组和那格列奈片组患者治疗16周后的糖化血红蛋白,空腹血糖、餐后1小时血糖、餐后两小时血糖,空腹胰岛素、餐后1小时胰岛素、餐后2小时胰岛素,空腹C肽、餐后1小时C肽、餐后2小时C肽与治疗前相比均有明显下降,但是两组间无显著差异。不良事件和不良反应的发生率较低,因此,口服米格列奈钙片在临床上是一种既安全又有效的的治疗2型糖尿病的途径。结论:本研究表明米格列奈钙片在治疗2型糖尿病,降低糖化血红蛋白,控制空腹血糖、餐后1小时血糖、餐后2小时血糖,空腹胰岛素、餐后1小时胰岛素、餐后2小时胰岛素,空腹C肽、餐后1小时C肽、餐后2小时C肽方面作用与那格列奈片相似,疗效确切,安全性好,值得在2型糖尿病患者中推广使用。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of minicalinide calcium tablets in the treatment of type 2 diabetes mellitus. Methods: 56 patients with type 2 diabetes mellitus were randomly divided into two groups: the experimental group (n = 28) and the control group (n = 28). The experimental group was treated with miglinide calcium tablet for 16 weeks, and the control group was treated with naglinide tablet 3 times a day. Before and after treatment, the levels of HbA1cn, FBG, PPG1, PPG2, fasting insulin, postprandial insulin, fasting C-peptide, fasting insulin, fasting C-peptide and postprandial C-peptide were measured before and after treatment. The therapeutic effects of C peptide at 2 hours postprandial were compared. To compare the efficacy and safety of Miglinide calcium tablets in the treatment of type 2 diabetes mellitus. Results: the glycosylated hemoglobin, fasting blood glucose, postprandial blood glucose, fasting insulin, postprandial insulin and postprandial insulin were measured in the calcium and nateglinide groups. Fasting C peptide, 1 hour postprandial C peptide and 2 hour postprandial C peptide were significantly lower than those before treatment, but there was no significant difference between the two groups. The incidence of adverse events and adverse reactions is low. Therefore, oral miglinide calcium tablets is a safe and effective way to treat type 2 diabetes mellitus clinically. Conclusion: this study shows that Miglinide calcium tablets can treat type 2 diabetes mellitus, reduce glycosylated hemoglobin, control fasting blood glucose, postprandial blood glucose, fasting insulin, postprandial insulin. Two hours postprandial insulin, fasting C-peptide, 1 hour postprandial C-peptide and 2 hour postprandial C-peptide were similar to nateglinide tablets.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R587.1

【相似文献】